Closing slide
• Presentation of Cold-to-Hot MOA at ESMO 2025 [2Q Calendar 2025]
• Secured Funding for Expanded Access Program [4Q Calendar 2025]
• FDA clearance of TNBC Phase II Trial and Expanded Access Program protocol(s) [4Q
Calendar 2025]
• mCRC protocol submission to FDA regarding inclusion and timing of ICls in current
Phase II mCRC trial [4Q Calendar 2025]
• Initiation of TNBC Expanded Access Program [1Q Calendar 2026]
• Initial PD-L1 readouts from mCRC trial [1Q Calendar 2026]
• Initiation of Phase II TNBC Trial [1H Calendar 2026]